Lupus Clinical Trials in Ohio

18 recruiting studies across 2 cities

Browse by City

All Trials in Ohio

Phase

Trial	Phase	Sponsor	Dist.
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study	Phase 2	Children's Hospital Medical Center, Cincinnati	<1 mi
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus	Phase 2/3	Biogen	<1 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants	Phase 3	AstraZeneca	<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)	Phase 1	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN	—	GlaxoSmithKline	<1 mi
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants	Phase 1	GlaxoSmithKline	<1 mi
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus	Phase 1	Luminary Therapeutics	<1 mi
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial	Phase 4	NephroNet, Inc.	<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	Phase 1	National Cancer Institute (NCI)	<1 mi
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease	Phase 1	Fate Therapeutics	<1 mi
Lupus Landmark Study: A Prospective Registry and Biorepository	—	Lupus Research Alliance	<1 mi
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)	—	Ampel BioSolutions, LLC	<1 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V	Phase 2	Novartis Pharmaceuticals	<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases	Phase 2	Amgen	<1 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)	Phase 2	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)	Phase 2	Boehringer Ingelheim	11 mi
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).	Phase 3	Novartis Pharmaceuticals	11 mi
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus	Phase 3	Janssen Research & Development, LLC	11 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.